BRAF and metastatic melanoma: Patients treated with immunotherapy, targeted therapy, or combined targeted therapy with BRAF inhibitors had significantly better OS than patients treated with standard metastatic melanoma treatment options, e.g., local radiotherapy and/or chemotherapy, before December 2016.